Chugai Looks Overseas As Challenges Loom At Home
Executive Summary
Chugai sees continued overseas growth, helped by sales through parent and licensee Roche and a brace of novel products, as key to overcoming challenges at home over the next few years.
You may also be interested in...
Shire Solid But Hemophilia Challenges Looming?
Shire puts in solid results in last full year before Takeda acquisition, with 4% sales growth and strong cash flow, but there was some weakness in hematology stemming from lower ex-US prices and rising competition.
Chugai May Not Win Race For $500m Neuromyelitis Optica Market, But May Best Soliris On Ease Of Use
While Chugai’s satralizumab may not be odds on to win the race for approval, it may beat Alexion’s Soliris on ease of use with a regimen of subcutaneous application once a month versus Soliris’ fortnightly IV.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.